world
Health platform launches blood test screening for 130 conditions affecting women
A new service uses an annual blood draw to calculate risk probabilities for multiple conditions. The company plans to add a menstrual fluid test later this year.
New York PostAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
A health platform launched today that screens users for more than 130 conditions through a blood sample and questionnaire. After users complete a health history form, the service arranges a blood draw of roughly 80 milliliters at a laboratory or through a mobile phlebotomist.
The platform then analyzes biomarkers alongside clinical data to estimate the likelihood of conditions that disproportionately affect women.
Screening process and limitations The platform does not provide a diagnosis.
Results include probability levels for endometriosis, fibroids, early menopause, hypothyroidism, Lyme disease, and premenstrual dysphoric disorder, among others. Users receive information on potential next steps and can repeat the screening annually to track changes such as the transition into perimenopause.
Pricing and availability The base screening costs $499 and is eligible for HSA and FSA accounts but is not covered by insurance. The service is not offered in New York or New Jersey.
Menstrual fluid test in development The company plans to introduce a menstrual fluid test later this year that examines biomarkers and reproductive tissue for endometriosis detection. The same sample type may later support assessments of fertility outcomes and the vaginal microbiome.
